Date: 2012-01-17
Type of information: Licensing agreement
Compound: XenoGene™ Technology
Company: Complegen (USA) Boehringer Ingelheim (Germany)
Therapeutic area:
Type agreement: licensing
Action mechanism: CompleGen\'s XenoGene™ technology uses the power of genetics to identify allosteric inhibitors that are selective for specific protein targets.
Disease:
Details: CompleGen announced that they have executed a non-exclusive services agreement regarding CompleGen\'s XenoGene™ technology. Boehringer Ingelheim\'s discovery team will apply the technology to explore targets that are not easily accessible by other discovery platforms.
Financial terms:
Latest news:
